58 results about "Abdominal aneurysm" patented technology

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention discloses an abdominal aortic aneurysm risk screening method based on HbA1c multiple risk markers, and aims to solve the problems that AAA screening in the prior art depends on a single marker, is lack of nonlinear analysis and is insufficient in application tool, a comprehensive risk prediction model is constructed by integrating HbA1c, proteomics data and non-genetic factors, a nonlinear risk relationship is revealed, and the risk of the abdominal aortic aneurysm is predicted to be the risk of the abdominal aortic aneurysm of the abdominal aortic aneurysm of the abdominal aortic aneurysm. And an application tool is developed, visual display of the morbidity probability and the risk level of n years is provided, a personalized screening strategy is supported, and the accuracy and practicability of AAA early screening are improved.

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The application belongs to the technical field of biological medicine, and relates to application of a CXCL14 inhibitor in preparation of a drug for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the gender difference of abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and its receptor CXCR4, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress of abdominal aortic aneurysm, reduces the degree of collagen degradation and elastic fiber damage, and thus inhibits the pathological progress of abdominal aortic aneurysm. The application provides a new target and drug combination for precise treatment of male abdominal aortic aneurysm, and has clear clinical application value.

1. Name of the product in this design: Packaging box for early risk warning kit for abdominal aortic aneurysm. 2. Purpose of this design: For the outer packaging of an early risk warning kit for abdominal aortic aneurysm. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key features: the front view.

The invention relates to the technical field of biological medicines, and particularly relates to a method for researching the influence of silencing or inhibiting a UBE2G1 gene on the growth of abdominal aortic aneurysm by constructing a UBE2G1 gene function deletion mouse model. Results show that silence or inhibition of UBE2G1 gene expression can inhibit growth of abdominal aortic aneurysm, alleviate destruction of elastic fibers of arterial tissues, reduce levels of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in a body and inhibit polarization of macrophage M1. According to the invention, a certain theoretical basis is provided in the aspect of treatment of abdominal aortic aneurysm by means of biotechnology, and the UBE2G1 gene (or protein) can be used as a drug target for treatment of abdominal aortic aneurysm.

The invention discloses an abdominal aortic aneurysm serum protein fingerprint detection and analysis method and system based on an LASSO regression algorithm. The method comprises the following steps: by optimizing a serum sample pretreatment process and combining an MALDI-TOFMS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) mass spectrometry technology and high-throughput proteomics data analysis, screening differentially expressed proteins related to occurrence, development and rupture of abdominal aortic aneurysm in serum; and further constructing a risk assessment model based on the key protein combination by using an LASSO machine learning algorithm. The method provided by the invention has the advantages of high sensitivity and good specificity, can effectively distinguish abdominal aortic aneurysm patients from normal people, can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, and provides important tools and bases for clinical early diagnosis, risk stratification and personalized treatment decision.

The application discloses a method for separating and culturing primary vascular smooth muscle cells from human abdominal aortic wall, and relates to the technical field of human cell culture. The method comprises the following steps: obtaining a collagenase A solution; adding the collagenase A solution to a treated human abdominal aortic aneurysm wall tissue sample and then cutting the sample; transferring the cut human abdominal aortic aneurysm wall tissue sample to a 37-degree cell culture box for culture; centrifuging a cell suspension obtained after termination of digestion; discarding supernatant, resuspending cell precipitate, and repeating centrifugation for three times; resuspending the cell precipitate again, uniformly transferring the cell precipitate to a T25 culture bottle after blowing, and placing the cell precipitate in a 37-degree cell culture box for culture; when a wave peak and wave trough state appears, the cell precipitate is digested and subcultured by using 0.25% trypsin, and then the cell precipitate is transferred to a new T25 culture bottle; and the cell precipitate is subcultured normally to the P3 generation and then stored in liquid nitrogen, so that the cell damage is prevented and the activity and proliferation capacity of the cell are maintained.

The invention provides an abdominal aortic aneurysm early prediction model construction method, system and device and a medium. According to the method, a balanced research queue is constructed through fusion of multi-modal data (ultrasonic images, biochemical indexes and lipidomics) and tendency score matching, so that the accuracy of early risk identification of the abdominal aortic aneurysm and the model robustness are remarkably improved; furthermore, on the basis of a risk migration strategy, the discrimination capability of the complex deep learning model is migrated to a simplified logistic regression model which only needs a simplest lipid feature set and basic demographic information, so that high prediction performance is maintained, model lightweight, parameter immobilization and clinical interpretability are realized, the detection cost and the operation complexity are greatly reduced, and the detection efficiency is improved. A high-precision risk prediction technology can be conveniently deployed in a basic medical scene, and finally an abdominal aortic aneurysm early screening solution with high precision, high interpretability and wide applicability is formed.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

The invention relates to an abdominal aortic aneurysm filling system and treatment system, the filling system comprises a filling assembly, the filling assembly comprises at least two filling blocks, each filling block adopts shape memory polymer foam, and each filling block has a compressed loading state and an implantation state of expanding at a preset position; the interventional catheter is used for containing the filling assembly to implement interventional delivery, and the filling blocks are sequentially arranged in the extending direction of the interventional catheter in the loading state; the connecting shaft is arranged in the interventional catheter in a sliding mode, the far-end portion of the connecting shaft sequentially penetrates through and is connected with the filling blocks so as to carry the filling blocks to be released from the far-end side of the interventional catheter into the abdominal aortic aneurysm, and the far-end portion of the connecting shaft is configured to be spirally wound around a space axis in a pre-shaping mode. The surgical operation process is simplified, the filling blocks are arranged relatively orderly after being released and expanded, the space filling rate is high, and the surgical treatment effect is further improved.

The invention belongs to the technical field of medicines, and particularly relates to a prodrug for supplementing NAD < + >, which is an NAMPT agonist YB8, and an application of the prodrug in prevention and treatment of abdominal aortic aneurysm. The invention discloses a prodrug YB8 capable of specifically activating nicotinamide phosphoribosyltransferase (NAMPT), and the prodrug YB8 can effectively improve the level of NAD + (nicotinamide adenine dinucleotide) in cells, so that the degenerative change of a vascular structure is slowed down, the purposes of protecting blood vessels and treating abdominal aortic aneurysm are achieved, and the YB8 is proved to be used as a specific activator of NAMPT for the first time. The multi-target treatment effect is achieved by improving the blood vessel NAD + level; the discovery provides a brand new strategy for the drug treatment of abdominal aortic aneurysm, and the treatment advantages are as follows: ultrasonic imaging proves that the tumor progress can be obviously inhibited; the discovery lays an important foundation for developing clinical treatment of abdominal aortic aneurysm based on NAD + metabolism regulation.

The invention discloses application of a biomarker in preparation of a product for diagnosing abdominal aortic aneurysm, a kit and a use method, the biomarker has the advantages of high sensitivity, strong specificity and high accuracy, and the detection method is simple and rapid and has important significance in early screening of abdominal aortic aneurysm. The biomarker is any one of the following exosome proteins or a combination thereof: fibrinogen beta chain, fibronectin, lysosome related membrane glycoprotein 2 and histone H4.

The invention relates to application of a JAML gene in preparation of an abdominal aortic aneurysm resisting medicine, and belongs to the technical field of biological medicine. The nucleotide sequence of the JAML gene is as shown in SEQ ID No.1. The application of the JAML gene in preparation of the abdominal aortic aneurysm resisting medicine comprises the following two aspects: (1) applying the JAML gene as an action target to preparation of the abdominal aortic aneurysm resisting medicine; and (2) applying the JAML gene as an action target to screening of drugs for resisting abdominal aortic aneurysm. According to the invention, a gene knockout mouse of which the smooth muscle specifically knockout JAML is constructed, and then the mouse abdominal aortic aneurysm model is constructed by subcutaneously pumping AngII, so that the morbidity of abdominal aortic aneurysm can be obviously reduced after the JAML gene is knocked out; therefore, a theoretical basis is provided for preparing or screening drugs or preparations for inhibiting smooth muscle cell JAML gene expression as alternative drugs or preparations for resisting abdominal aortic aneurysm.

A device of this application can include (i) an improved stent graft device having a collapsible conduit to provide sealable access to an aneurysmal sac during deployment or (ii) a multiport embolization sheath configured to be used conjunction with a stent graft device.

The invention relates to the technical field of image processing, in particular to an abdominal aortic aneurysm intracavitary isolation postoperative internal leakage diagnosis system based on an ultrasound contrast image.According to the method, ultrasound images of different parameters are collected at the same position, firstly, a first ultrasound image is adopted at the high working frequency, and a second ultrasound image is adopted at the high working frequency; then, a second ultrasonic image is collected at low working frequency; the first ultrasonic image and the second ultrasonic image are preprocessed through different preprocessing methods, then the first ultrasonic image is input into an artificial intelligence model to be used for determining the position of the aortic aneurysm, and then the position of the aortic aneurysm in the second ultrasonic image is obtained according to the position; and then inputting the aortic aneurysm in the second image into the artificial intelligence model, thereby realizing internal leakage diagnosis. By means of the mode, the situation that in the prior art, two kinds of ultrasonic images are subjected to image fusion through a complex algorithm and then diagnosis is conducted is avoided, the process is simple, and the diagnosis efficiency is improved.

The invention relates to the technical field of medical instruments, in particular to an abdominal aortic aneurysm cavity support auxiliary positioning device. An inner tube and a positioning assembly are coaxially arranged in the outer sheath tube in a sleeving manner; the outer sheath tube is connected with the near end of the inner tube, so that the relative positions of the outer sheath tube and the inner tube can be kept consistent; the positioning assembly is arranged on the periphery of the inner tube in a sleeving mode and can slide between the outer sheath tube and the inner tube. A penetrating through hole is formed in the center of the inner tube, and a guide wire can penetrate through the penetrating through hole and slide in the inner tube. The auxiliary positioning device for the abdominal aortic aneurysm cavity support is simple in structure, easy and convenient to operate and capable of effectively assisting in positioning a main body support short iliac branch opening in an abdominal aortic aneurysm cavity, the butt joint efficiency of the main body support short iliac branch and an iliac branch extension support is improved, the operation time is shortened, the operation risk is reduced, and ray damage is reduced.

The invention relates to application of an Arteridin gene as a biomarker in preparation of a product for auxiliary diagnosis of abdominal aortic aneurysm, clinical specimens and animal experiments find that the expression of Arteridin in occurrence of abdominal aortic aneurysm is remarkably increased, which indicates that Arteridin can be used as the biomarker for auxiliary diagnosis of abdominal aortic aneurysm; the invention also relates to a product for down-regulating the expression of Arterin and an application of the product in preparation of drugs for treating abdominal aortic aneurysm, the product comprises siRNA and shRNA of a targeted Arterin gene and AAV for coding the sequence of the shRNA, and after specific knockdown of Arterin by smooth muscle cells is realized, in an Elatase-induced abdominal aortic mouse model, the expression of Arterin is reduced, and the expression of Arterin is reduced. The diameter of the aneurysm is reduced, the occurrence rate is reduced, the elastin destruction degree is reduced, the expression quantity of vascular remodeling genes MMP2 and MMP9 is reduced, and the difference is obvious compared with that of a control group; the result shows that Arteridin is expected to become a target spot for treating abdominal aortic aneurysm.

The invention discloses an application of Anti-TSLP (Transcriptional Stem Like Protein) in prevention or treatment of abdominal aortic aneurysm. The Anti-TSLP is an anti-TSLP (Transcriptional Stem Like Protein) monoclonal antibody. The application of Anti-TSLP as a monoclonal antibody drug in prevention or treatment of abdominal aortic aneurysm is found for the first time. By intraperitoneal injection of Anti-TSLP and neutralization of TSLP pro-inflammatory cytokines, macrophage M1 / M2 phenotype can be effectively regulated, macrophage-mediated inflammatory response can be regulated and controlled, abdominal aortic aneurysm can be relieved, and a potential treatment scheme is provided for precise treatment of patients with clinical abdominal aortic aneurysm.

The invention relates to the technical field of medical instruments, and discloses a form-adaptive aortic dissection false cavity or aneurysm cavity thrombosis promoting embolism device which comprises a double-layer metal grid spindle-shaped skeleton of a hollow structure. Comprising a connecting point at the upper end and the lower end and an arc-shaped side face connected between the two points. The isolating membrane is located between the double-layer metal grid fusiform skeletons, and the double-layer metal grid fusiform skeletons are small in size after being compressed, can be quickly released and automatically adapt to the shape of an aortic dissection false cavity or an aneurysm cavity, so that the aneurysm cavity or the false cavity is fully blocked, and thrombosis of the aneurysm cavity or the false cavity is promoted. The device is simple in structure, convenient to operate, capable of adapting to the shape of an interlayer false cavity to be fully filled, good in blood flow isolation effect, capable of rapidly promoting thrombosis and remodeling of the false cavity, free of reverse compression of a true cavity and capable of being applied to occasions where embolism needs to be conducted on abdominal aortic aneurysm cavities and other branch arteries.

The application discloses application of CCR6 gene in preparation of an anti-abdominal aortic aneurysm medicine and belongs to the technical field of medicines. The application selects CCR6-siRNA interference technology, constructs an adeno-associated virus expression vector, inhibits expression of a mouse CCR6 gene, and constructs a mouse abdominal aortic aneurysm model by subcutaneous pumping of angiotensin II, finds that inhibition of the CCR6 gene can significantly reduce the incidence of abdominal aortic aneurysm and inhibit the occurrence and development of abdominal aortic aneurysm, and provides a theoretical and experimental basis for preparation and screening of a medicine or preparation for inhibiting expression of the CCR6 gene as a candidate medicine or preparation for resisting abdominal aortic aneurysm. The application prepares an adeno-associated virus for inhibiting the CCR6 gene, and finds that inhibition of the CCR6 gene can significantly inhibit the occurrence and development of abdominal aortic aneurysm by injecting the adeno-associated virus for inhibiting the CCR6 gene into a mouse tail vein.

This invention discloses the application of selenoprotein M in the preparation of drugs for treating abdominal aortic aneurysms. This invention also provides the application of selenoprotein M in the preparation of drugs for reducing macrophage inflammation. This invention can effectively delay the progression of abdominal aortic aneurysms and reduce macrophage inflammation, and has broad prospects for medical applications.

This invention discloses the application of ML-SA5, a highly specific small molecule agonist of TRPML1, for the preparation of drugs against aortic aneurysms or aortic dissections. An aortic aneurysm model was constructed, and an aortic dissection model was established using Fbn1 point mutations. The severity of aortic aneurysms or aortic dissections in control and experimental mice was assessed using small animal ultrasound and aortic morphology staining. Results showed that intraperitoneal injection of ML-SA5 or overexpression of TRPML1 significantly reduced abdominal aortic aneurysm / dissection lesions in mice; it also reduced elastic fiber degradation and smooth muscle cell destruction in abdominal aortic aneurysms, decreased the increase in media thickness and collagen fiber deposition in aortic dissections, further improving the progression and histopathological damage of abdominal aortic aneurysms / dissections. This drug showed good therapeutic effects in animal experiments, with high safety and few toxic side effects, and can be used as a drug to inhibit the progression of aortic aneurysms / dissections.

The invention provides application of an adeno-associated virus overexpressing CTH in preparation of drugs for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CTH is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

The application discloses a kind of abdominal aortic aneurysm progression prediction method and system based on cross-modal knowledge distillation, by collecting the blood of target object;The blood of target object is detected by blood protein fingerprint marker concentration, and blood protein fingerprint marker includes matrix metalloproteinase-12, calcitonin related polypeptide-alpha, urine regulator, nerve injury induced protein-1, glycosylated hemoglobin A1c, fibroblast growth factor-9;Based on blood protein fingerprint marker concentration, Student-net of cross-modal knowledge distillation is called to calculate abdominal aortic aneurysm risk;Wherein, the input of Teacher-net of cross-modal knowledge distillation includes CTA image feature and pathological section feature, and the category probability vector output by Student-net is aligned with the category probability vector output by Teacher-net;Output abdominal aortic aneurysm risk grade and preset year abdominal aortic aneurysm occurrence / progression / rupture three event probability.Precise prediction is carried out to the development of aortic aneurysm disease.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a nano system for targeted photothermal-chemotherapy synergistic treatment of abdominal aortic aneurysm as well as a preparation method and application thereof. The system is a mesoporous polydopamine-coated gold nanorod cluster (AuM) nanoparticle co-loaded with one or more traditional Chinese medicine ingredients and modified by c(RGDfK) cyclic peptide. The preparation comprises the following steps: taking chloroauric acid and dopamine hydrochloride as raw materials, synthesizing AuM in the presence of a reaming agent and a template agent by a one-step method; further loading a large amount of drugs in the mesopores to obtain drug-loaded nanoparticles; and finally grafting a targeting peptide on the surface of the nanoparticles to obtain the final product. The system has the characteristics of targeting macrophages and smooth muscle cells, NIR-Ⅱ photothermal conversion and photothermal response drug release. The in-vitro and in-vivo experimental results show that the system can realize local photothermal treatment and precise drug release under NIR-Ⅱ light, and inhibit aortic dilation through various cell behaviors, thereby providing a nano preparation with clinical transformation potential for precise treatment of abdominal aortic aneurysm.

A stent graft for surgical delivery in a target site of a patient to treat an aortic aneurysm. The stent graft includes a graft formed of graft material including a first portion to be received by a lower portion of an aorta that is relatively straight, and a second portion to be received by an upper portion of an aorta that is curved. The stent graft includes a stent attached to the graft including stent members. In a first orientation, the first and second portions of the graft material are folded between the stent members over first and second adjacent portions of the graft to form a first pleat and a second pleat. In a second orientation, the second pleat has a graft space between corresponding stent members on a greater curvature side of the stent graft that is greater than on a lesser curvature side of the stent graft.

The invention belongs to the field of biological medicines, particularly discloses an application of NiMn-PB in preparation of an abdominal aortic aneurysm protection medicine, and discloses that NiMn-PB can obviously improve degradation of an aortic elastic fibrous layer caused by Ang II treatment and can relieve immune cell infiltration, inflammation release, ferroptosis and angiogenesis in aorta; after Ang II treatment, NiMn-PB is used for intervention, occurrence and development of the abdominal aortic aneurysm induced by Ang II can be relieved, and it is indicated that NiMn-PB can be used for preparing the medicine for relieving the abdominal aortic aneurysm.

This invention belongs to the field of biomedical technology, specifically relating to the application of metabolic markers in the preparation of products for diagnosing abdominal aortic aneurysms. The metabolic markers include 5-δ-hydroxybutylhydantoin, 1-α-amino acid, and PGF. 2α The present invention provides one or more of the following metabolites: D-pyroglutamic acid, nicotinic glucuronide, cysteine ​​glutathione disulfide, or Trp-P-1. Experiments have confirmed that the seven metabolites, alone or in combination, have good specificity and sensitivity as metabolic markers for diagnosing abdominal aortic aneurysms.